Reconstructive Surgery for Bladder Exstrophy
Treatment for Urogenital Congenital Anomalies
Effectiveness
90%
Safety Score
50%
Clinical Trials
2
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate anatomical correction, functional continence achieved over years with multi-stage surgeries
Treatment Duration
Multiple surgeries over childhood (birth to adolescence), lifelong follow-up
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$5,000
Side Effect Mgmt:$10,000
Total Annual:$100,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
6
Outcome-Based Costs
Cost per Responder
$142,857
Comparison vs Palliative Care / No Definitive Reconstruction
Cost Difference
$0/year
Same cost
QALY Difference
+6.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Reconstructive Surgery for Bladder Exstrophy Outcomes
for Urogenital Congenital Anomalies
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+70%
Common Side Effects
Bladder prolapse
+10%
Bladder neck incontinence
+30%
Urinary tract infection
+35%
Urethral stricture/fistula
+15%
Renal deterioration
+15%
Reoperation for complications
+60%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Reconstructive Surgery for Bladder Exstrophy in Urogenital Congenital Anomalies
Early Versus Delayed Closure of Bladder Exstrophy in Female Patients
NCT07794540COMPLETEDNA
124 participants
INTERVENTIONAL
Peshawar, Pakistan
Started: Jan 28, 2021
eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness
NCT04150120COMPLETEDNA
720 participants
INTERVENTIONAL
Copenhagen, Denmark +6 more
Started: Oct 15, 2019